NVSEF - Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
2024-03-12 12:09:42 ET
Summary
- Bicycle Therapeutics plc results from the phase 1/2 Duravelo-1 study, using BT8009 for the treatment of patients with metastatic urothelial carcinoma, expected in the 2nd half of 2024.
- Data from BT5528 [Bicycle toxin conjugate tech] and BT7480 [Bicycle tumor-targeted immune cell agonist] clinical candidates targeting solid tumors, expected in the 2nd half of 2024.
- A data updated on the Bicycle Radio Conjugate technology program is expected in mid-2024.
- Bicycle Therapeutics' $526.4 million in cash as of December 31st 2023; Enough cash on hand to fund its operations into 2026.
There is a major inflection point expected to happen with Bicycle Therapeutics plc ( BCYC ) in the 2nd half of 2024. That is when it expects to complete dosing of its open-label phase 1/2 Duravelo-1 study and then to also report additional clinical data from it....
Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point